Ticker: AURA

Aura Biosciences, Inc. (NASDAQ: AURA) - What's happening inside Short version: the company accelerated clinical and manufacturing work on its lead VDC candidate belzupacap sarotalocan (bel‑sar), funded that activity with a May 16, 2025 follow‑on offering, and materially increased its cash and equ...

Aura Biosciences, Inc. (NASDAQ: AURA) declared a net loss of $27.5 million during Q1 2025, compared to a loss of $19.7 million in Q1 2024. Its operations are heavily dependent on a clinical-stage product, bel-sar, which has not yet reached the market. Key Points and Statistics: Income Statement ...